Deterioration in glucose metabolism in pancreatic transplant recipients after conversion from azathioprine to cyclosporine.
Six recipients of combined pancreas and kidney transplants displayed a deterioration in glucose tolerance when the immunosuppressive therapy was changed from azathioprine-prednisolone to cyclosporine-prednisolone. Because at the same time the plasma C-peptide level increased it seems that insulin resistance, rather than reduced insulin secretion, caused the impairment in glucose tolerance. The condition was found to be reversible.
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism*; D003524:Cyclosporins / Q000009:adverse effects* / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D016030:Kidney Transplantation; D008875:Middle Aged; D016035:Pancreas Transplantation; D011239:Prednisolone / Q000627:therapeutic use
D001786:Blood Glucose; D003524:Cyclosporins; D011239:Prednisolone; D001379:Azathioprine